| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 42 | 2023 | 711 | 7.570 |
Why?
|
| Crohn Disease | 27 | 2023 | 730 | 5.760 |
Why?
|
| Inflammatory Bowel Diseases | 28 | 2023 | 549 | 4.910 |
Why?
|
| Colon | 15 | 2023 | 496 | 2.540 |
Why?
|
| MicroRNAs | 8 | 2020 | 534 | 2.080 |
Why?
|
| Colitis | 9 | 2021 | 239 | 1.880 |
Why?
|
| Colonic Neoplasms | 8 | 2020 | 558 | 1.560 |
Why?
|
| Inflammation | 7 | 2023 | 923 | 1.270 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2023 | 52 | 1.190 |
Why?
|
| Colectomy | 6 | 2023 | 167 | 1.120 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 938 | 1.120 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 103 | 1.090 |
Why?
|
| Vitamin D | 4 | 2021 | 261 | 1.020 |
Why?
|
| Hospitalization | 6 | 2019 | 851 | 0.980 |
Why?
|
| Retrospective Studies | 30 | 2023 | 8496 | 0.960 |
Why?
|
| Ileum | 4 | 2023 | 159 | 0.950 |
Why?
|
| Humans | 84 | 2023 | 86678 | 0.920 |
Why?
|
| Renin-Angiotensin System | 4 | 2019 | 133 | 0.910 |
Why?
|
| Aspirin | 2 | 2021 | 156 | 0.880 |
Why?
|
| Cyclosporine | 3 | 2019 | 234 | 0.880 |
Why?
|
| Ustekinumab | 2 | 2020 | 47 | 0.870 |
Why?
|
| Middle Aged | 36 | 2020 | 25040 | 0.870 |
Why?
|
| Clostridium Infections | 3 | 2020 | 125 | 0.860 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 977 | 0.860 |
Why?
|
| Adult | 40 | 2023 | 25659 | 0.850 |
Why?
|
| Postoperative Complications | 6 | 2022 | 2207 | 0.820 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2020 | 62 | 0.820 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 54 | 0.820 |
Why?
|
| Fatigue | 1 | 2022 | 174 | 0.810 |
Why?
|
| Colonoscopy | 8 | 2023 | 267 | 0.810 |
Why?
|
| Ileal Diseases | 2 | 2019 | 25 | 0.800 |
Why?
|
| Leukocyte L1 Antigen Complex | 5 | 2023 | 39 | 0.770 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 166 | 0.750 |
Why?
|
| Male | 44 | 2023 | 40988 | 0.740 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.740 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.740 |
Why?
|
| Ulcer | 2 | 2022 | 36 | 0.730 |
Why?
|
| Gastrointestinal Agents | 6 | 2020 | 161 | 0.730 |
Why?
|
| Intestinal Mucosa | 7 | 2019 | 797 | 0.720 |
Why?
|
| Female | 43 | 2023 | 44550 | 0.690 |
Why?
|
| Piperidines | 7 | 2022 | 181 | 0.660 |
Why?
|
| Patient Admission | 1 | 2019 | 112 | 0.650 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 80 | 0.650 |
Why?
|
| Kynurenine | 1 | 2018 | 20 | 0.650 |
Why?
|
| Severity of Illness Index | 9 | 2021 | 1802 | 0.640 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1384 | 0.640 |
Why?
|
| Tryptophan | 1 | 2018 | 90 | 0.630 |
Why?
|
| Dysbiosis | 1 | 2018 | 70 | 0.620 |
Why?
|
| Proctocolectomy, Restorative | 4 | 2022 | 87 | 0.620 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.620 |
Why?
|
| Caveolin 1 | 1 | 2017 | 20 | 0.620 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 231 | 0.610 |
Why?
|
| Young Adult | 16 | 2020 | 5980 | 0.610 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 35 | 0.600 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 263 | 0.600 |
Why?
|
| Collagen Type I | 1 | 2017 | 62 | 0.600 |
Why?
|
| Recurrence | 7 | 2023 | 1139 | 0.590 |
Why?
|
| Colonic Pouches | 3 | 2022 | 67 | 0.590 |
Why?
|
| Focal Adhesions | 1 | 2017 | 69 | 0.580 |
Why?
|
| DNA Methylation | 3 | 2020 | 628 | 0.570 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2019 | 930 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 1197 | 0.560 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 24 | 0.530 |
Why?
|
| Pyrimidines | 5 | 2022 | 370 | 0.530 |
Why?
|
| Pouchitis | 3 | 2021 | 44 | 0.520 |
Why?
|
| Seasons | 1 | 2016 | 223 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2014 | 21 | 0.510 |
Why?
|
| Remission Induction | 7 | 2023 | 722 | 0.510 |
Why?
|
| Treatment Outcome | 16 | 2023 | 7998 | 0.510 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2014 | 55 | 0.500 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 88 | 0.500 |
Why?
|
| Hematoma | 1 | 2015 | 104 | 0.500 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 199 | 0.500 |
Why?
|
| Case-Control Studies | 6 | 2021 | 1807 | 0.490 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2014 | 7 | 0.490 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 296 | 0.480 |
Why?
|
| Aged | 15 | 2021 | 18423 | 0.470 |
Why?
|
| ras Proteins | 1 | 2014 | 128 | 0.470 |
Why?
|
| Patient Readmission | 1 | 2017 | 329 | 0.470 |
Why?
|
| Intestine, Small | 1 | 2015 | 303 | 0.460 |
Why?
|
| Adolescent | 11 | 2020 | 8984 | 0.420 |
Why?
|
| Pyrroles | 4 | 2020 | 184 | 0.400 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.400 |
Why?
|
| Receptors, Calcitriol | 4 | 2019 | 129 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 645 | 0.390 |
Why?
|
| Infliximab | 4 | 2020 | 151 | 0.390 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 190 | 0.370 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2023 | 153 | 0.370 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 696 | 0.370 |
Why?
|
| Risk Factors | 10 | 2020 | 5420 | 0.360 |
Why?
|
| Transcriptome | 2 | 2018 | 580 | 0.360 |
Why?
|
| Feces | 3 | 2021 | 319 | 0.340 |
Why?
|
| Logistic Models | 5 | 2018 | 1188 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 683 | 0.330 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 1169 | 0.320 |
Why?
|
| Secondary Prevention | 2 | 2019 | 162 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2023 | 4214 | 0.320 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 273 | 0.310 |
Why?
|
| Carcinogenesis | 3 | 2019 | 195 | 0.310 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 109 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 1376 | 0.300 |
Why?
|
| Signal Transduction | 8 | 2019 | 3243 | 0.300 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 728 | 0.300 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 481 | 0.290 |
Why?
|
| Cryoglobulinemia | 1 | 2006 | 6 | 0.290 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 94 | 0.280 |
Why?
|
| Chronic Disease | 3 | 2022 | 973 | 0.280 |
Why?
|
| Fatty Liver | 1 | 2007 | 125 | 0.280 |
Why?
|
| Angiotensin II | 4 | 2019 | 95 | 0.270 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 126 | 0.270 |
Why?
|
| Disease Progression | 5 | 2019 | 1532 | 0.270 |
Why?
|
| Registries | 3 | 2020 | 703 | 0.270 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 3642 | 0.260 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 300 | 0.250 |
Why?
|
| Down-Regulation | 4 | 2020 | 506 | 0.250 |
Why?
|
| Biological Products | 3 | 2021 | 143 | 0.240 |
Why?
|
| Indans | 1 | 2023 | 31 | 0.240 |
Why?
|
| Hepatitis C | 1 | 2006 | 210 | 0.230 |
Why?
|
| Oxadiazoles | 1 | 2023 | 46 | 0.230 |
Why?
|
| Calcineurin Inhibitors | 2 | 2021 | 54 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 386 | 0.220 |
Why?
|
| Mice | 12 | 2022 | 11356 | 0.220 |
Why?
|
| Time Factors | 4 | 2019 | 5214 | 0.220 |
Why?
|
| Enterocolitis | 1 | 2022 | 12 | 0.220 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 76 | 0.210 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2019 | 40 | 0.210 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1921 | 0.210 |
Why?
|
| Prognosis | 3 | 2020 | 3680 | 0.210 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 59 | 0.210 |
Why?
|
| Steroids | 2 | 2020 | 177 | 0.210 |
Why?
|
| ErbB Receptors | 3 | 2016 | 485 | 0.210 |
Why?
|
| Losartan | 2 | 2019 | 42 | 0.210 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2020 | 45 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1579 | 0.210 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 147 | 0.200 |
Why?
|
| Anastomosis, Surgical | 2 | 2022 | 267 | 0.200 |
Why?
|
| Chicago | 2 | 2018 | 1380 | 0.200 |
Why?
|
| HCT116 Cells | 3 | 2017 | 151 | 0.200 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 115 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 144 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2022 | 2768 | 0.200 |
Why?
|
| Calbindin 2 | 1 | 2021 | 5 | 0.200 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 5 | 0.200 |
Why?
|
| Th17 Cells | 2 | 2019 | 80 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2019 | 256 | 0.200 |
Why?
|
| Phenotype | 5 | 2022 | 2380 | 0.200 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 37 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 738 | 0.190 |
Why?
|
| Colonic Diseases | 1 | 2021 | 65 | 0.190 |
Why?
|
| Endoscopy | 3 | 2021 | 332 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 154 | 0.190 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.190 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 20 | 0.190 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 91 | 0.180 |
Why?
|
| Stem Cells | 1 | 2022 | 351 | 0.180 |
Why?
|
| Animals | 13 | 2022 | 26590 | 0.180 |
Why?
|
| Cytosine | 1 | 2020 | 127 | 0.180 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 112 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 16 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2019 | 25 | 0.170 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 1464 | 0.170 |
Why?
|
| Incidence | 2 | 2016 | 1578 | 0.170 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2019 | 19 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1001 | 0.170 |
Why?
|
| Interleukin-8 | 2 | 2016 | 86 | 0.170 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 267 | 0.160 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 40 | 0.160 |
Why?
|
| Health Resources | 1 | 2019 | 76 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6513 | 0.160 |
Why?
|
| Prednisolone | 1 | 2018 | 41 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 295 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1621 | 0.160 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.160 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 244 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 79 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2231 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 120 | 0.150 |
Why?
|
| Histocytochemistry | 1 | 2017 | 130 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 315 | 0.150 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 9 | 0.150 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1992 | 0.140 |
Why?
|
| Zinc | 1 | 2017 | 92 | 0.140 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 44 | 0.140 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 79 | 0.140 |
Why?
|
| United States | 5 | 2020 | 6681 | 0.140 |
Why?
|
| Genome, Human | 1 | 2020 | 756 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 458 | 0.130 |
Why?
|
| JC Virus | 1 | 2015 | 5 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 2271 | 0.130 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 13 | 0.130 |
Why?
|
| Natalizumab | 1 | 2015 | 21 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 184 | 0.130 |
Why?
|
| Cadherins | 1 | 2016 | 151 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2020 | 715 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2020 | 1565 | 0.130 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2426 | 0.130 |
Why?
|
| DNA | 1 | 2020 | 1294 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 376 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 33 | 0.130 |
Why?
|
| Sacroiliitis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2016 | 458 | 0.120 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2014 | 24 | 0.120 |
Why?
|
| Arthralgia | 1 | 2014 | 36 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 372 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 293 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 584 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2014 | 502 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 1230 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2014 | 233 | 0.110 |
Why?
|
| DNA, Complementary | 1 | 2013 | 393 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 427 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2013 | 476 | 0.100 |
Why?
|
| Adipokines | 1 | 2011 | 19 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 3095 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 2264 | 0.100 |
Why?
|
| Lectins | 1 | 2011 | 84 | 0.100 |
Why?
|
| Epithelial Cells | 4 | 2019 | 669 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 307 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 157 | 0.090 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.090 |
Why?
|
| Apoptosis | 4 | 2019 | 1683 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2379 | 0.090 |
Why?
|
| Microbiota | 1 | 2016 | 381 | 0.090 |
Why?
|
| Infant | 1 | 2016 | 3047 | 0.090 |
Why?
|
| Child | 2 | 2022 | 6928 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2016 | 3613 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 782 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1852 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1540 | 0.090 |
Why?
|
| Caco-2 Cells | 2 | 2019 | 123 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2019 | 286 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1753 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2021 | 303 | 0.080 |
Why?
|
| Diet | 1 | 2011 | 443 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2819 | 0.080 |
Why?
|
| Inpatients | 2 | 2021 | 298 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 916 | 0.080 |
Why?
|
| Propensity Score | 2 | 2018 | 136 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2019 | 90 | 0.070 |
Why?
|
| Transcriptional Activation | 2 | 2020 | 280 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 78 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2007 | 160 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 895 | 0.070 |
Why?
|
| Rituximab | 1 | 2006 | 116 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1981 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2601 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2019 | 816 | 0.060 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1621 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2706 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 2357 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Dextran Sulfate | 2 | 2013 | 68 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2023 | 170 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1924 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2898 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 61 | 0.050 |
Why?
|
| Osteonectin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| Karyopherins | 1 | 2020 | 14 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2022 | 192 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 76 | 0.050 |
Why?
|
| CpG Islands | 1 | 2020 | 151 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2020 | 258 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 928 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 166 | 0.050 |
Why?
|
| Cell Survival | 1 | 2022 | 969 | 0.040 |
Why?
|
| DNA, Circular | 1 | 2019 | 8 | 0.040 |
Why?
|
| France | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Claudin-2 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 39 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 159 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 52 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2013 | 445 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 57 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 78 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 677 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 81 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 311 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 93 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 826 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 526 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2020 | 1074 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1041 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 684 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 91 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 778 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 861 | 0.040 |
Why?
|
| Medical Records | 1 | 2017 | 119 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 22 | 0.040 |
Why?
|
| Hydralazine | 1 | 2016 | 20 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2016 | 50 | 0.040 |
Why?
|
| Spiro Compounds | 1 | 2016 | 25 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2018 | 181 | 0.040 |
Why?
|
| Fumarates | 1 | 2016 | 26 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 1106 | 0.040 |
Why?
|
| Diet, Western | 1 | 2016 | 37 | 0.040 |
Why?
|
| Amides | 1 | 2016 | 60 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1208 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 462 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 55 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 339 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 560 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 394 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 433 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 241 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 26 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 680 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.030 |
Why?
|
| Azathioprine | 1 | 2015 | 125 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1673 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 747 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2894 | 0.030 |
Why?
|
| Tight Junctions | 1 | 2013 | 149 | 0.030 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 279 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 352 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 63 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2011 | 82 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 557 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 113 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2504 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 196 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 269 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 3968 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 758 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1961 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 3992 | 0.020 |
Why?
|